Leading the Way in Life Science Technologies

GEN Exclusives

More »

BioMarket Trends

More »
Nov 1, 2009 (Vol. 29, No. 19)

Sparing Patients the Needle Remains a Priority

Patients and Healthcare Providers Should Benefit from Proliferation of Needle-Free Systems

  • Product Development

    The needle-free market is expanding to include a greater number of pharmaceutical and biotechnology drugs. Developers of needle-free devices understand the drawbacks and weaknesses of their technologies and seek to improve their products in order to expand the market. As more drugs are developed to be delivered by needle-free devices, the market size is expected to grow.

    The price of needle-free devices is expected to erode in the coming years, which, in turn, is expected to increase sales volume, spurring revenues for the manufacturers. Increased awareness and patient acceptance is expected to play a crucial role in the market penetration of the needle-free technology.

    The efficacy and safety of new devices being developed and anticipated to be launched in the coming years will determine the market acceptance. Some of the applications expected to be key to the success of needle-free technologies include vaccines, protein and peptide drugs, gene delivery, and insulin. Needle-free devices have come a long way to the present state and are playing an increasingly important role in the novel drug delivery technologies markets.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »